Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2NAV

NMR solution structure of Ex-4[1-16]/pl14a

2NAV の概要
エントリーDOI10.2210/pdb2nav/pdb
関連するPDBエントリー2NAW
NMR情報BMRB: 25948
分子名称Exendin-4, Alpha/kappa-conotoxin pl14a chimera (1 entity in total)
機能のキーワードagonist, toxin
由来する生物種Heloderma suspectum, Conus planorbis (Gila monster, Planorbis cone)
細胞内の位置Secreted: Q0N4U8
タンパク質・核酸の鎖数1
化学式量合計3161.51
構造登録者
Schroeder, C.I.,Swedberg, J.E.,Craik, D.J. (登録日: 2016-01-11, 公開日: 2016-05-04, 最終更新日: 2024-11-27)
主引用文献Swedberg, J.E.,Schroeder, C.I.,Mitchell, J.M.,Fairlie, D.P.,Edmonds, D.J.,Griffith, D.A.,Ruggeri, R.B.,Derksen, D.R.,Loria, P.M.,Price, D.A.,Liras, S.,Craik, D.J.
Truncated Glucagon-like Peptide-1 and Exendin-4 alpha-Conotoxin pl14a Peptide Chimeras Maintain Potency and alpha-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
J.Biol.Chem., 291:15778-15787, 2016
Cited by
PubMed Abstract: Glucagon-like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regulator of normal glucose metabolism, and exogenous GLP-1R agonist therapy is a promising avenue for the treatment of type 2 diabetes mellitus. To date, the development of therapeutic GLP-1R agonists has focused on producing drugs with an extended serum half-life. This has been achieved by engineering synthetic analogs of GLP-1 or the more stable exogenous GLP-1R agonist exendin-4 (Ex-4). These synthetic peptide hormones share the overall structure of GLP-1 and Ex-4, with a C-terminal helical segment and a flexible N-terminal tail. Although numerous studies have investigated the molecular determinants underpinning GLP-1 and Ex-4 binding and signaling through the GLP-1R, these have primarily focused on the length and composition of the N-terminal tail or on how to modulate the helicity of the full-length peptides. Here, we investigate the effect of C-terminal truncation in GLP-1 and Ex-4 on the cAMP pathway. To ensure helical C-terminal regions in the truncated peptides, we produced a series of chimeric peptides combining the N-terminal portion of GLP-1 or Ex-4 and the C-terminal segment of the helix-promoting peptide α-conotoxin pl14a. The helicity and structures of the chimeric peptides were confirmed using circular dichroism and NMR, respectively. We found no direct correlation between the fractional helicity and potency in signaling via the cAMP pathway. Rather, the most important feature for efficient receptor binding and signaling was the C-terminal helical segment (residues 22-27) directing the binding of Phe(22) into a hydrophobic pocket on the GLP-1R.
PubMed: 27226591
DOI: 10.1074/jbc.M116.724542
主引用文献が同じPDBエントリー
実験手法
SOLUTION NMR
構造検証レポート
Validation report summary of 2nav
検証レポート(詳細版)ダウンロードをダウンロード

247947

件を2026-01-21に公開中

PDB statisticsPDBj update infoContact PDBjnumon